Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 141 (4), 671-89

Current Clinical Regulation of PI3K/PTEN/Akt/mTOR Signalling in Treatment of Human Cancer


Current Clinical Regulation of PI3K/PTEN/Akt/mTOR Signalling in Treatment of Human Cancer

Hui Jun Lim et al. J Cancer Res Clin Oncol.


Purpose: PTEN is an essential tumour suppressor gene which encodes a phosphatase protein that antagonises the PI3K/Akt/mTOR antiapoptotic pathway. Impairment of this tumour suppressor pathway potentially becomes a causal factor for development of malignancies. This review aims to assess current understanding of mechanisms of dysfunction involving the PI3K/PTEN/Akt/mTOR pathway linked to tumorigenesis and evaluate the evidence for targeted therapy directed at this signalling axis.

Methods: Relevant articles in scientific databases were identified using a combination of search terms, including "malignancies", "targeted therapy", "PTEN", and "combination therapy". These databases included Medline, Embase, Cochrane Review, Pubmed, and Scopus.

Results: PI3K/PTEN expression is frequently deregulated in a majority of malignancies through genetic, epigenetic, and post-transcriptional modifications. This contributes to the upregulation of the PI3K/Akt/mTOR pathway which has been the focus of intense clinical studies. Targeted agents aimed at this pathway offer a novel treatment approach in a variety of haematologic malignancies and solid tumours. Compared to single-agent use, greater response rates were obtained in combination regimens, supporting further investigation of suitable drug combinations in a broad spectrum of malignancies.

Conclusion: Activation of the PI3K/PTEN/Akt/mTOR pathway is implicated both in the pathogenesis of malignancies and development of resistance to anticancer therapies. Therefore, PI3K/Akt/mTOR inhibitors are a promising therapeutic option, in association with systemic cytotoxic and biological therapies, to enable sustained clinical outcomes in cancer treatment. Therapeutic strategies could be tailored according to appropriate biomarkers and patient-specific mutation profiles to maximise benefit of combination therapies.

Similar articles

See all similar articles

Cited by 48 articles

See all "Cited by" articles


    1. Clin Cancer Res. 2010 Jun 1;16(11):3057-66 - PubMed
    1. Acta Neuropathol. 2007 Mar;113(3):295-302 - PubMed
    1. Curr Med Chem. 2007;14(19):2009-23 - PubMed
    1. Nat Rev Mol Cell Biol. 2012 Apr 04;13(5):283-96 - PubMed
    1. Nature. 2011 Feb 10;470(7333):214-20 - PubMed

MeSH terms